Astrazeneca Share News (AZN)

AstraZeneca to present new cardiovascular, renal drug data in US

(Alliance News) - AstraZeneca PLC on Monday said it will present new data on cardiovascular and renal disease drugs in the US between Thursday and Monday next week.

AstraZeneca's Ultomiris treatment gets good results from Phase 3 trial

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 trial results for its Ultomiris treatment showed a "significant" reduction in the risk of relapse in adults with neuromyelitis optica spectrum disorder.

Study confirms AstraZeneca jab's higher risk of very rare clot

(Alliance News) - AstraZeneca PLC's Covid vaccine has been linked to a 30% higher risk of getting a very rare blood clotting condition compared to the Pfizer Inc jab, a large international study said Thursday.

TOP NEWS: AstraZeneca hails survival rates of breast cancer drugs

(Alliance News) - AstraZeneca PLC on Wednesday said its breast cancer drugs capivasertib and camizestrant significantly improved progression-free survival in a phase 3 and 2 trial respectively.

LONDON MARKET OPEN: Sterling climbs above USD1.15, euro above parity

(Alliance News) - London's FTSE 100 index moved lower at the open on Wednesday, as the pound continued to climb higher on the potential for the stability that a Rishi Sunak premiership could bring to Westminster.

AstraZeneca breast cancer drug shows 'significant' improvement in trial

(Sharecast News) - AstraZeneca said its capivasertib breast cancer drug combined with Faslodex hormone treatment demonstrated a "statistically significant and clinically meaningful improvement" in progression-free patient (PFS) survival during a late-stage trial.

TOP NEWS: AstraZeneca's Fasenra fails to meet trial's primary endpoint

(Alliance News) - AstraZeneca PLC on Tuesday said that its Fasenra treatment failed to meet one of its two primary endpoints in its Messina Phase 3 trial in eosinophilic esophagitis.

AstraZeneca says Fasenra fails to meet one trial endpoint

(Sharecast News) - AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.

AstraZeneca treatment gets FDA approval for US liver cancer patients

(Alliance News) - AstraZeneca PLC on Monday said one of its treatments has been approved in the US for treating adults with unresectable liver cancer.

AstraZenenca liver cancer combination treatment approved by FDA

(Sharecast News) - AstraZeneca said its Imjudo drug, in combination with Imfinzi, hadbeen approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer, the company said on Monday.

UK stocks end volatile session higher after Prime Minister Liz Truss resigns

Liz Truss to quit as UK prime minister next week

*

TOP NEWS: AstraZeneca says Evusheld shows promise on Covid variants

(Alliance News) - AstraZeneca PLC on Thursday said that new analyses from a phase 3 treatment trial show the potential of its Covid drug Evusheld to reduce severity and mortality.

LONDON BROKER RATINGS: HSBC lifts Marston's; Barclays cuts Flutter

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

LONDON MARKET CLOSE: Stocks down as BoE confirms end to bond-buying

(Alliance News) - Stock prices in London closed in the red on Wednesday, as discouraging economic data and mixed signals from the UK's central bank weighed on investor sentiment.

AstraZeneca to show 'exceptional' data on neuromyelitis drug Ultomiris

(Alliance News) - AstraZeneca PLC on Wednesday said its subsidiary Alexion Pharmaceuticals Inc, which focuses on rare diseases, will publish "new data showing significant advances" regarding the treatment for a form of neuromyelitis with its drug Ultomiris.